Hydreight Technologies Inc. (“
Hydreight” or
the
“Company”) (TSXV:NURS)(OTCQB:HYDTF)(FSE:S06) a
mobile clinical network and medical platform which enables
flexible, at-home medical services across 50 states in the United
States, is excited to announce that healthcare providers and their
patients now have access to Semaglutide through the Hydreight
platform.
Semaglutide injections are commonly used to
treat type 2 diabetes. It can also be used together with diet and
exercise to help control blood sugar and has become popular to help
with weight management. Semaglutide is a glucagon-like peptide-1
(GLP-1) receptor agonist and is only available with a doctor’s
prescription and needs to be injected on a regular basis.
According to Goldman Sachs, it is projected that
by 2030, the global market for anti-obesity medications (AOMs)
could grow by more than 16 times to $100 billion. Based on current
trends, over half of the global population will be overweight or
obese by 2035, compared to 38% in 2020, according to a World
Obesity Atlas 2023 forecast.1
Shane Madden, CEO of Hydreight
commented, “This is a significant inflection point for Hydreight
and a pivotal point for our business. We have seen huge demand in
the United States for medications like Semaglutide to help with
weight management. Our revolutionary technology platform allows
doctors and nurses to connect with patients and pharmacy networks
to provide continuous care and improve patient outcomes. Adding
access to Semaglutide through our platform is the first step in our
shift from preventative medicine to essential healthcare, and we
are only just getting started.”
Hydreight is revolutionizing mobile medicine by
building the largest mobile clinical network in the United States
which operates in over 650 cities nationally. Currently, Hydreight
is utilizing its proprietary platform and mobile network to provide
end to end care and has built the only platform that can now host
the provision of fully integrated approach to patient care which
includes, lab tests, doctors’ prescriptions, drug delivery, drug
administering, patient monitoring and regular follow ups across the
United States.
Hydreight has a robust product offering and
continues to add products to its legacy IV drip therapy solution.
Over the last few months, Hydreight has added aesthetics and
filler, as well as NAD+ to its platform. Next year, Hydreight's
platform plans to expand to accommodate lab testing and 12 blood
tests that can be taken at home or office with the support of a
nurse. All these products allow healthcare providers using the
Hydreight platform to provide a higher level of medicine and
provide a pathway to shift into medical essentials.
1.
https://www.goldmansachs.com/intelligence/pages/anti-obesity-drug-market.html
About Hydreight Technologies
Inc.
Hydreight Technologies Inc. is building the
largest mobile clinic network in the United States. Its
proprietary, fully integrated platform hosts a network of nearly
3,000 nurses, over 100 doctors and a pharmacy network across 50
states. The platform includes a built-in, easy-to-use suite of
fully integrated tools for accounting, documentation, sales,
inventory, booking, and managing patient data, which enables
licensed healthcare professionals to provide services directly to
patients at home, office or hotel. Hydreight empowers nurses, med
spa technicians, and other licensed healthcare professionals to
deliver services independently, on their own terms, or to add
mobile services to existing location-based operations. The
Hydreight platform hosts a 503B pharmacy network servicing all 50
states and is closely affiliated with a U.S. certified e-script and
telemedicine provider network that provides services in over 650
cities and growing.
On behalf of the Board of Directors
Shane MaddenDirector and Chief Executive OfficerHydreight
Technologies Inc.
ContactEmail: ir@hydreight.com; Telephone:
(480) 790 6886
Cautionary Note Regarding
Forward-Looking Information
This press release contains statements which
constitute “forward-looking information” within the meaning of
applicable securities laws, including statements regarding the
plans, intentions, beliefs and current expectations of the Company
with respect to future business activities and operating
performance. Forward-looking information is often identified by the
words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”,
“anticipate”, “believe”, “estimate”, “expect”, “Approximately” or
similar expressions and includes information regarding the launch
date of MedicalMedIV.com, and the anticipated effect on bookings
and customer retention rates.
Investors are cautioned that forward-looking
information is not based on historical facts but instead reflects
the Company’s management’s expectations, estimates or predictions
concerning future results or events based on the opinions,
assumptions and estimates of management considered reasonable at
the date the statements are made. Although the Company believes
that the expectations reflected in such forward-looking information
are reasonable, such information involves risks and uncertainties,
and undue reliance should not be placed on such information, as
unknown or unpredictable factors could have material adverse
effects on future results, performance or achievements of the
Company. Among the key factors that could cause actual results to
differ materially from those projected in the forward-looking
information are the following: the ability to obtain requisite
regulatory and other approvals with respect to the business
operated by the Company and/or the potential impact of the listing
of the Company’s shares on the TSXV on relationships, including
with regulatory bodies, employees, suppliers, customers and
competitors; changes in general economic, business and political
conditions, including changes in the financial markets; changes in
applicable laws; compliance with extensive government regulation;
and the diversion of management time as a result of being a
publicly listed entity. This forward-looking information may be
affected by risks and uncertainties in the business of the Company
and market conditions.
Should one or more of these risks or
uncertainties materialize, or should assumptions underlying the
forward-looking information prove incorrect, actual results may
vary materially from those described herein as intended, planned,
anticipated, believed, estimated or expected. Although the Company
has attempted to identify important risks, uncertainties and
factors which could cause actual results to differ materially,
there may be others that cause results not to be as anticipated,
estimated or intended. The Company does not intend, and does not
assume any obligation, to update this forward-looking information
except as otherwise required by applicable law.
Neither TSXV nor its Regulation Services
Provider (as that term is defined in policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this release.
This press release does not constitute an offer
of securities for sale in the United States. The securities being
offered have not been, nor will they be, registered under the
United States Securities Act of 1933, as amended, and such
securities may not be offered or sold within the United States
absent U.S. registration or an applicable exemption from U.S.
registration requirements.
Hydreight Technologies (TSXV:NURS)
Historical Stock Chart
From Apr 2024 to May 2024
Hydreight Technologies (TSXV:NURS)
Historical Stock Chart
From May 2023 to May 2024